Clinical trials: Disease Exacerbation
Chronic Obstructive Pulmonary Disease
Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations
This study is designed to assess the effect of once-daily QVA149 on COPD exacerbations in patients with severe to very severe COPD.
- Trial name
- SPARK (NCT01120691)
- Testing
- QVA149, NVA237, tiotropium
- Where
- 342 sites in United States, Argentina and 26 more
- Volunteers
- 2,224 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia, Schizoaffective Disorder
A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
The purpose of this study is to evaluate the efficacy and safety of ziprasidone in acute exacerbation of schizophrenia or schizoaffective disorder, including patients with recent onset of symptoms
- Trial name
- NCT00645229
- Testing
- Ziprasidone
- Where
- Portugal
- Volunteers
- 1 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
COPD Exacerbation
Non-contact Proactive Remote Monitoring of COPD Exacerbations
The goal of this observational study is to determine if a COPD exacerbation can be detected early in its onset. The main questions it aims to answer are: Can an exacerbation be detected before the person recognizes they are…
- Trial name
- DetectEx (NCT05598983)
- Where
- United Kingdom
- Volunteers
- 75 people
- Sponsor
- Life Detection Technologies
Schizophrenia
Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With Schizophrenia
The purpose of this study is to determine the efficacy, safety, tolerability and pharmacokinetics (PK) properties of CPL500036 compound (PDE10a inhibitor) in patients with an acute exacerbation of schizophrenia after 28 days of…
- Trial name
- NCT05278156
- Testing
- CPL500036 - low dose, CPL500036 - high dose
- Where
- 16 sites in Hungary, Poland and 1 more
- Volunteers
- 189 people
- Sponsor
- Celon Pharma SA
Asthma
Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients
Primary objective of the study is to evaluate whether patients with severe eosinophilic asthma who have received long-term treatment with mepolizumab (at least 3 years) need to maintain treatment with mepolizumab to continue to…
- Trial name
- NCT02555371
- Testing
- Mepolizumab 100mg
- Where
- 73 sites in United States, Argentina and 12 more
- Volunteers
- 306 people
- Sponsor
- GlaxoSmithKline
COPD, COPD Exacerbation
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD
The purpose of this study is to compare CHF 5993 with CHF 1535 in improving lung function, reducing moderate and severe COPD exacerbations, and other clinical efficacy and safety outcomes in the target subject population.
- Trial name
- TRITON (NCT04320342)
- Testing
- Beclomethasone Dipropionate, Glycopyrronium Bromide, Formoterol Fumarate
- Where
- 436 sites in United States, Argentina and 8 more
- Volunteers
- 3,406 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Bronchitis
A Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil In the Treatment of Chronic Bronchitis
Identifying the role of antibiotics in the treatment of subjects with a microbiologically documented acute exacerbation of chronic bronchitis (AECB) is the purpose of this clinical trial.
- Trial name
- NCT00255983
- Testing
- Faropenem medoxomil
- Where
- United States
- Volunteers
- 491 people
- Sponsor
- Replidyne
Schizophrenia
A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (15 mg QD and 30 mg QD) in…
- Trial name
- NCT05227703
- Testing
- Emraclidine 15 mg, Emraclidine 30 mg
- Where
- 26 sites in United States, Bulgaria and 1 more
- Volunteers
- 391 people
- Sponsor
- AbbVie
Asthma, Copd
Inhaler Trainer Efficacy Study
This will be a randomized, controlled, clinical trial. The investigators aim to determine the feasibility of and efficacy of the Inhaler Trainer Device for ongoing inhaler skill training.
- Conditions
- Asthma, Copd, Acute Exacerbation of COPD
- Trial name
- NCT06461403
- Testing
- Inhaler Trainer System, Initial Inhaler Use Assessment, Inhaler Use Instruction
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Koronis Biomedical Technologies
COPD Exacerbation
A Feasibility Study of Wearable Device in Assessing Respiratory Condition Change of Patients With Exacerbation of COPD
The study will include daily SenseGuard measurement of patients hospitalized with exacerbations of COPD. from admission to discharge.
- Trial name
- NCT05153122
- Testing
- SenseGuard
- Where
- 2 sites in Germany, Israel
- Volunteers
- 15 people
- Sponsor
- NanoVation
Asthma, COPD
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
This observational study evaluates whether lung sound analysis with LungPass device can be used to differentiate exacerbation and stable state asthma and COPD.
- Trial name
- NCT05145894
- Testing
- Lung auscultation with LungPass device (electronic auscultation)
- Where
- Belarus
- Volunteers
- 200 people
- Sponsor
- Healthy Networks
Chronic Obstructive Pulmonary Disease
Effect of Remote Physiologic Monitoring (RPM) on Outcomes in COPD Patients
This pre/post study was a retrospective analysis of unplanned hospitalization rates in a cohort of COPD subjects started on remote physiologic monitoring (RPM) at a large, outpatient pulmonary practice.
- Trial name
- NCT05518981
- Testing
- Respiratory Remote Patient Monitor (Spire Health Tag)
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- Spire, Inc.
Chronic Obstructive Pulmonary Disease
A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD
The purpose of this study is to determine if SYMBICORT® delivered via a pressurized metered-dose inhaler, referred to as a pMDI, is effective in preventing COPD exacerbations.
- Trial name
- NCT00419744
- Testing
- Budesonide/formoterol (SYMBICORT) pMDI, Formoterol Turbuhaler
- Where
- 140 sites in United States, Argentina and 7 more
- Volunteers
- 1,200 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
COPD Remote Patient Monitoring Through Connected Devices
This study is a device study that will use a double-arm. It will integrate the ANNE ONE platform which continuously tracks enrolled COPD patients' vital signs and symptoms over the course of the study and digitally shares that…
- Trial name
- NCT05271474
- Testing
- ANNE ONE Platform
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Innovation Hub Enterprises
Pharyngitis Acute, Pharyngitis
Study to Evaluate the Efficacy and Safety of Different Doses of Graminidin With Anesthetic, a Metered Dose Topical Spray, in the Treatment of Acute Infectious and Inflammatory Pharyngeal Diseases Compared With Drug Septolete Total, Lozenges
This study aims to evaluete of tthe efficacy and safety of using different doses of the drug Grammidin with anesthetic, a metered dose topical spray, in the treatment of acute infectious and inflammatory pharyngeal diseases.
- Conditions
- Pharyngitis Acute, Pharyngitis, Nasopharyngitis, Exacerbation of Chronic Pharyngitis
- Trial name
- NCT06843018
- Testing
- Grammidin with anesthetic, Septolete Total
- Where
- 12 sites in Russia
- Volunteers
- 300 people
- Sponsor
- Valenta Pharm JSC
COPD Acute Exacerbation
Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)
This is a Phase 2, multicenter study in adult participants with an acute COPD exacerbation and type 2 inflammation
- Trial name
- NCT06940154
- Testing
- Rademikibart in prefilled syringe
- Where
- 52 sites in United States, Argentina and 4 more
- Volunteers
- 159 people
- Sponsor
- Connect Biopharm LLC
Protein Losing Enteropathy
Pilot/Ph I Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary to Single Ventricle Palliative Surgery
Protein Losing Enteropathy (PLE) is a serious medical condition that may develop in children and adults with congenital heart disease for which a palliative procedure known as the "Fontan procedure" has been performed.
- Trial name
- NCT01161641
- Testing
- ODSH at 0.125 mg/kg/h, ODSH at 0.375 mg/kg/h, ODSH at 0.250 mg/kg/h
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Jazz Pharmaceuticals
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Study to Evaluate the Clinical Value and Safety of Xiyanping Injection in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease(COPD) Based on Real-world Clinical Data
The primary objective is to evaluate the effect of Xiyanping injection on the treatment course of intravenous antibiotics for acute exacerbation of chronic obstructive pulmonary disease based on real-world clinical data, and to…
- Trial name
- XYP-202401 (NCT06754865)
- Testing
- Xiyanping injection+ antibiotic, Antibiotic
- Volunteers
- 1,140 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Asthma
Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care
ANCHOR is a prospective, phase IV, interventional, single-arm, open-label study of 1,500 adult participants with symptomatic asthma requiring the use of rescue therapy aimed to compare the asthma exacerbation rates before and…
- Trial name
- ANCHOR (NCT06422689)
- Testing
- Albuterol and budesonide inhalation aerosol
- Where
- 11 sites in United States
- Volunteers
- 1,511 people
- Sponsor
- AstraZeneca
SARS-CoV-2 Infection
Nitric Oxide Nasal Spray (NONS) To Treat and Prevent the Exacerbation of Infection in Individuals With Mild COVID-19
Primary: The primary objective of this study is to evaluate the efficacy of Nitric Oxide Nasal Spray combined with standard supportive care compared with standard supportive care alone in adult subjects with COVID-19 not…
- Trial name
- NCT05599919
- Testing
- Nitric Oxide
- Where
- 21 sites in India
- Volunteers
- 306 people, healthy volunteers welcome
- Sponsor
- Sanotize Research and Development corp.